The Bulgarian pharmaceutical company Sopharma made history by breaking on the Austrian market with a 100 per cent Bulgarian-manufactured drug, Bulgarian media reported on April 29 2010.Traditionally, the German and Austrian markets are considered as two of the most conservative markets in the world, where foreign-made drugs found it difficult to gain approval to be sold on the local markets.The Sopharma drug is called Nivalin and, according to the description on the company's website, was indicated during the convalescence and residual phase of poliomyelitis and is used for treating several other diseases.In Austria however, the drug is registered with the trademark Nivaject.